Gene and cell therapy on the acquisition and relapse-like binge drinking in a model of alcoholism: translational options
Author
dc.contributor.author
Israel Jacard, Yedy
Author
dc.contributor.author
Quintanilla González, María Elena
Author
dc.contributor.author
Ezquer, Fernando
Author
dc.contributor.author
Morales, Paola
Author
dc.contributor.author
Rivera Meza, Mario
Author
dc.contributor.author
Karahanian, Eduardo
Author
dc.contributor.author
Ezquer, Marcelo
Author
dc.contributor.author
Herrera Marschitz, Mario
Admission date
dc.date.accessioned
2019-10-15T12:25:32Z
Available date
dc.date.available
2019-10-15T12:25:32Z
Publication date
dc.date.issued
2019
Identifier
dc.identifier.issn
14765462
Identifier
dc.identifier.issn
09697128
Identifier
dc.identifier.other
10.1038/s41434-019-0064-9
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/171711
Abstract
dc.description.abstract
Studies reviewed show that lentiviral gene therapy directed either at inhibiting the synthesis of brain acetaldehyde generated from ethanol or at degrading brain acetaldehyde fully prevent ethanol intake by rats bred for their high alcohol preference. However, after animals have chronically consumed alcohol, the above gene therapy did not inhibit alcohol intake, indicating that in the chronic ethanol intake condition brain acetaldehyde is no longer the compound that generates the continued alcohol reinforcement. Oxidative stress and neuroinflammation generated by chronic ethanol intake are strongly associated with the perpetuation of alcohol consumption and alcohol relapse “binge drinking”. Mesenchymal stem cells, referred to as guardians of inflammation, release anti-inflammatory cytokines and antioxidant products. The intravenous delivery of human mesenchymal stem cells or the intranasal administration of mesenchymal stem cell-generated exosomes rever